Novel Diagnostic Approach for Lyme Disease Using Cell-Free DNA ID: 2024-012
A groundbreaking approach to Lyme Disease diagnostics through targeted sequencing of cell-free DNA.
Photo by rbkomar
Technology Overview
This technology involves a novel diagnostic method for Lyme Disease by detecting cell-free DNA (cfDNA) from Borrelia burgdorferi and other Lyme-causing bacteria in blood plasma. By focusing on targeted sequencing assays that identify small genomic fragments, this approach significantly enhances the sensitivity and specificity of Lyme Disease diagnostics. Utilizing the Oxford Nanopore platform, this method enables direct sequencing of fragmented, low-input DNA, offering a powerful tool for early and accurate disease detection.
Key Advantages
- Enhanced diagnostic sensitivity and specificity
- Ability to detect DNA at low concentrations
- Minimally invasive testing through blood plasma
- Reduction of PCR errors through direct sequencing
Problems Addressed
- Early and accurate detection of Lyme Disease
- Reduction of Lyme Disease misdiagnoses
- Identification of Lyme Disease in cases with low bacterial load
- Overcoming limitations of current diagnostic methods that require complete genomes
Additional Information
Technology ID: 2024-012
Sell Sheet: Download the Sell Sheet here
Market Analysis: Contact us for a more in-depth market report
Date Published: 28 March, 2025
Connect with the Tech Transfer to:
- Meet with the technology manager
- Receive additional information
- Request a marketing plan report